pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GLP-1 receptor · news · pharmadog
← back to GLP-1 receptor
News · GLP-1 receptor
471
stories
Oct 12, 26
Pharma’s $500B patent problem will come in waves — not as a cliff
biopharma dive
Oct 9, 26
FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts
biopharma dive
Oct 9, 26
Hengrui has become the go-to source of China biopharma innovation. What’s its secret?
fiercebiotech
Oct 8, 26
Eli Lilly and the LA Dodgers: A tale of 2 dynasties
biospace
Oct 8, 26
Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers
biospace
Oct 8, 26
Zealand, Roche’s ‘intriguing’ weight loss for amylin drug soured by blood sugar data
fiercebiotech
Oct 7, 26
WHO advises against obesity drugs for younger children
endpoints
Oct 7, 26
STAT+: Forbion raises $2.6 billion, its largest fundraise to date
stat
Oct 6, 26
FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues
biospace
Oct 6, 26
The top biopharma conferences in 2027
biopharma dive
Oct 5, 26
Significant stock movers of September: Viking soars, Longeveron slides
biospace
Oct 5, 26
Opinion: Energy drinks’ new college sports partnerships make them more dangerous than ever
stat
Oct 5, 26
Opinion: Will Claude ever win a Nobel Prize for medicine?
stat
Oct 5, 26
Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand
biospace
Oct 2, 26
What it’s like to wait for the call from the Nobel Prize committee
stat
Oct 2, 26
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
biospace
Oct 2, 26
#EASD26: Regeneron sees a future combining its obesity drug with lipid-lowering therapy
endpoints
Oct 1, 26
Mistrust in science and a juicy gene-editing lawsuit
stat
Oct 1, 26
3 takeaways from a European obesity scientific meeting
biopharma dive
Oct 1, 26
Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events
biospace
Oct 1, 26
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
biospace
Oct 1, 26
#EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapy
endpoints
Oct 1, 26
STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more
stat
Oct 1, 26
Trump administration appeals ruling blocking limits on international student visas
stat
Oct 1, 26
Opinion: Claude analyzed my genome in 30 minutes. Now we need standards for the results
stat
Oct 1, 26
Opinion: I studied GLP-1 use in children. The results are reassuring
stat
Oct 1, 26
STAT+: Two key Senate health committees face major shake-ups
stat
Oct 1, 26
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3
fiercebiotech
Oct 1, 26
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
fiercebiotech
Sep 30, 26
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
← prev
page 5 of 16
next →